精准医学时代肝硬化患者的β受体阻滞剂应用
综述探讨肝硬化患者非选择性β受体阻滞剂(NSBB)的个体化治疗窗口,涉及临床显著门静脉高压的争议、卡维地洛优于普萘洛尔、失代偿期风险及无创疗效预测的挑战。
要点
- 卡维地洛证据积累显示优于普萘洛尔,应作为一线治疗直至失代偿期。
- 难治性腹水、低血压和肾功能损害患者风险高,临床界定治疗窗口关闭。
- 缺乏可靠无创方法预测NSBB血流动力学应答是该领域主要挑战之一。
核心结论
- NSBB治疗窗口应从个体化角度界定,晚期失代偿阶段风险获益比恶化,难治性腹水、低血压和肾功能损害患者风险高。
- 卡维地洛优于普萘洛尔,应作为一线治疗直至失代偿期。
- 缺乏可靠无创方法预测NSBB血流动力学应答是该领域主要挑战之一。
研究设计与样本
- 综述,旨在从更个体化角度描绘肝硬化中NSBB的治疗窗口。
主要发现
- 尽管瞬时弹性成像有助于排除临床显著门静脉高压,但缺乏稳健数据支持无静脉曲张患者使用NSBB。
- 多数数据基于普萘洛尔,但积累证据提示卡维地洛更优。
- 晚期失代偿阶段风险获益比似乎恶化,难治性腹水、低血压和肾功能损害患者风险高。
关键数值与推荐
- 卡维地洛应作为一线治疗直至失代偿期。
- 难治性腹水、低血压和肾功能损害临床界定治疗窗口关闭。
- 缺乏可靠无创方法预测NSBB血流动力学应答。
临床怎么用
- 原文未据此给出推荐。
局限性
- 缺乏稳健数据支持无静脉曲张患者使用NSBB。
- 缺乏可靠无创方法预测NSBB血流动力学应答。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
For decades, non-selective beta-blockers (NSBBs) have been the standard of care for the primary and secondary prevention of bleeding from oesophageal varices. However, several questions regarding the best clinical use of NSBBs remain unanswered and new data continue to emerge. Herein, we aim to delineate the therapeutic window of NSBBs in cirrhosis from a more individualised perspective. We address the current controversy of widening the therapeutic window and prescribing NSBBs to all patients with clinically significant portal hypertension. Although transient elastography is useful to rule-in clinically significant portal hypertension, we lack robust data supporting the use of NSBBs in patients without varices. While most data are based on propranolol, accumulating evidence suggests that carvedilol is superior and should be the first-line treatment until the decompensated stage. The clinical risk-to-benefit ratio appears to deteriorate in advanced decompensated stages and the risk of harm is high in patients with refractory ascites, low blood pressure and renal impairment, which clinically define closure of the therapeutic window. We also critically review non-invasive surrogates and biomarkers for predicting the haemodynamic response to NSBBs and confirm that the absence of reliable non-invasive methods is one of the main challenges facing the field.
引用
- Albillos A, Krag A. Beta-blockers in the era of precision medicine in patients with cirrhosis. J Hepatol. 2022. PMID: 36529293. doi:10.1016/j.jhep.2022.12.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。